5 F-203 is reported to induce DNA damage and decrease growth of breast cancer cells [39], while tapinarof is an FDA approved AHR agonist used to treat psoriasis and atopic dermatitis and has been shown to increase the sensitivity of cancer cell lines to RBN2397 [30]. Here, AHR is linked to breast carcinoma.